These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Fosfomycin: the characteristics, activity, and use in critical care. Hashemian SMR; Farhadi Z; Farhadi T Ther Clin Risk Manag; 2019; 15():525-530. PubMed ID: 30988619 [TBL] [Abstract][Full Text] [Related]
45. Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Pogue JM; Neelakanta A; Mynatt RP; Sharma S; Lephart P; Kaye KS Clin Infect Dis; 2014 Dec; 59 Suppl 6():S388-93. PubMed ID: 25371515 [TBL] [Abstract][Full Text] [Related]
46. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716 [TBL] [Abstract][Full Text] [Related]
47. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471 [TBL] [Abstract][Full Text] [Related]
48. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit. Guervil DJ; Chau T Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425 [TBL] [Abstract][Full Text] [Related]
49. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Falagas ME; Kasiakou SK Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037 [TBL] [Abstract][Full Text] [Related]
50. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Kontopidou F; Plachouras D; Papadomichelakis E; Koukos G; Galani I; Poulakou G; Dimopoulos G; Antoniadou A; Armaganidis A; Giamarellou H Clin Microbiol Infect; 2011 Nov; 17(11):E9-E11. PubMed ID: 21939468 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Demir T; Buyukguclu T Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831 [TBL] [Abstract][Full Text] [Related]
52. Multidrug-resistant Gram-negative infections: the use of colistin. Michalopoulos AS; Karatza DC Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945 [TBL] [Abstract][Full Text] [Related]
54. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs. Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723 [TBL] [Abstract][Full Text] [Related]
55. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Gardiner BJ; Mahony AA; Ellis AG; Lawrentschuk N; Bolton DM; Zeglinski PT; Frauman AG; Grayson ML Clin Infect Dis; 2014 Feb; 58(4):e101-5. PubMed ID: 24170195 [TBL] [Abstract][Full Text] [Related]
56. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa. Di X; Wang R; Liu B; Zhang X; Ni W; Wang J; Liang B; Cai Y; Liu Y J Antibiot (Tokyo); 2015 Sep; 68(9):551-5. PubMed ID: 25805069 [TBL] [Abstract][Full Text] [Related]
57. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. ; Guan X; He L; Hu B; Hu J; Huang X; Lai G; Li Y; Liu Y; Ni Y; Qiu H; Shao Z; Shi Y; Wang M; Wang R; Wu D; Xie C; Xu Y; Yang F; Yu K; Yu Y; Zhang J; Zhuo C Clin Microbiol Infect; 2016 Mar; 22 Suppl 1():S15-25. PubMed ID: 26627340 [TBL] [Abstract][Full Text] [Related]
58. Fosfomycin: Resurgence of an old companion. Sastry S; Doi Y J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259 [TBL] [Abstract][Full Text] [Related]
59. Re: Is Fosfomycin a Potential Treatment Alternative for Multidrug-Resistant Gram-Negative Prostatitis? Schaeffer EM J Urol; 2015 Dec; 194(6):1642. PubMed ID: 26582669 [No Abstract] [Full Text] [Related]
60. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives. Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]